Federal Register / Vol. 73, No. 188 / Friday, September 26, 2008 / Notices 55859 

Bethesda, MD 20892–5452, (301) 594–8898, 

barnardm@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Translational 

Research. 

Date: October 29, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Michele L. Barnard, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 753, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8898, 

barnardm@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Gastrointestinal 

Programs. 

Date: November 13, 2008. 

Time: 7:45 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn National Airport, 2650 

Jefferson Davis Highway, Arlington, VA 

22202. 

Contact Person: Michael W. Edwards, PhD, 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 750, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8886, 

edwardsm@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 18, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22605 Filed 9–25–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, ITVC 

Conflicts. 

Date: October 15, 2008. 

Time: 10 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. (Telephone 

Conference Call) 

Contact Person: Enid Light, PhD, Scientific 

Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Boulevard, Room 6132, MSC 

9608, Bethesda, MD 20852–9608, 301–443– 

0322, elight@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, 

National Research Service Award (NRSA) 

Institutional Research Training Grants. 

Date: October 20, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites Hotel, 4300 Military 

Road, Washington, DC 20015. 

Contact Person: Vinod Charles, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6151, MSC 9606, 

Bethesda, MD 20892–9606, 301–443–1606. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, 

Pathway to Independence (PI) Award. 

Date: October 28, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Megan Libbey, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6148, MSC 9609, 

Rockville, MD 20852, 301–402–6807, 

libbeym@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel Aids 

Applications. 

Date: November 15, 2008. 

Time: 10 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. (Telephone 

Conference Call) 

Contact Person: Enid Light, PhD, Scientific 

Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Boulevard, Room 6132, MSC 

9608, Bethesda, MD 20852–9608, 301–443– 

0322, elight@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: September 18, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–22607 Filed 9–25–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of Benztropinamine 

Analogs To Treat Psychiatric and 

Neurological Disorders 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent Application 

No. 60/689,746, filed June 10, 2005, 

now abandoned [HHS Ref. No. E–089– 

2005/0–US–01]; PCT Patent Application 

No. PCT/US2006/22401, filed June 7, 

2006, now abandoned [HHS Ref. No. E– 

089–2005/0–US–02]; U.S. Patent 

Application No. 11/917,036, filed 

December 10, 2007 [HHS Ref. No. E– 

089–2005/0–US–03]; European Patent 

Application No. 06772641.4, filed 

December 7, 2007, which published as 

1888064 on February 20, 2008 [HHS 

Ref. No. E–089–2005/0–EP–04]; 

Australian Patent Application No. 

2006258035, filed November 30, 2007 

[HHS Ref. No. E–089–2005/0–AU–05]; 

Japanese Patent Application No. 2008– 

515947, filed December 7, 2007 [HHS 

Ref. No. E–089–2005/0–JP–06]; and 

Canadian Patent Application No. 

2609577, filed November 23, 2007 [HHS 

Ref. No. E–089–2005/0–CA–07], all of 

which are entitled ‘‘Benztropinamine 

Analogs as Dopamine Uptake 

Inhibitors’’ (Inventors: Amy Newman 

and Jonathan Katz, NIDA) to Shire LLC, 

having an office in at least Basingstoke, 

United Kingdom. The patent rights in 

these inventions have been assigned to 

the United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the use 

of benztropinamine analogs, 


jlentini on PROD1PC65 with NOTICES